De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Perspective Therapeutics Beheer

Beheer criteriumcontroles 1/4

De CEO Perspective Therapeutics' is Thijs Spoor, benoemd in Feb2023, heeft een ambtstermijn van 1.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.46M, bestaande uit 34.7% salaris en 65.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.031% van de aandelen van het bedrijf, ter waarde $ 277.07K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.6 jaar en 1.7 jaar.

Belangrijke informatie

Thijs Spoor

Algemeen directeur

US$1.5m

Totale compensatie

Percentage CEO-salaris	34.7%
Dienstverband CEO	1.7yrs
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	1.6yrs
Gemiddelde ambtstermijn bestuur	1.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Thijs Spoor's beloning veranderd ten opzichte van Perspective Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$52m
Mar 31 2024	n/a	n/a	-US$50m
Dec 31 2023	US$1m	US$506k	-US$37m

Compensatie versus markt: De totale vergoeding ($USD 1.46M ) Thijs } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.23M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Thijs te vergelijken met de prestaties van het bedrijf.

CEO

Thijs Spoor (52 yo)

1.7yrs

Tenure

US$1,458,996

Compensatie

Mr. Johan M. Spoor, also known as Thijs, is Chief Executive Officer and Director at Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) since February 05, 2023. He founded AzurRx BioPharma, Inc...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Johan Spoor	CEO & Director	1.7yrs	US$1.46m	0.031% $ 262.1k
Jonathan Hunt	CFO and Principal Financial & Accounting Officer	5.8yrs	US$1.17m	0.053% $ 454.3k
Markus Puhlmann	Chief Medical Officer	1.7yrs	US$900.09k	0.20% $ 1.7m
Shane Cobb	Executive Vice President of Operations	1.2yrs	geen gegevens	geen gegevens
Michael Schultz	Chief Science Officer	no data	geen gegevens	2.2% $ 18.7m
Andrew Bright	Executive Vice President of Brachytherapy	1.5yrs	geen gegevens	geen gegevens
Amos Hedt	Chief Business Strategy Officer	no data	geen gegevens	geen gegevens
Frances Johnson	Chief Innovation Officer	no data	geen gegevens	2.2% $ 18.7m
David Hauser	Senior Vice President of Clinical Operations	no data	geen gegevens	geen gegevens
Steve Keefe	Senior Vice President of Clinical Development	less than a year	geen gegevens	geen gegevens

1.6yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CATX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.6 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Johan Spoor	CEO & Director	1.7yrs	US$1.46m	0.031% $ 262.1k
Robert Williamson	Independent Director	1.7yrs	US$320.06k	0.063% $ 539.9k
Frank Morich	Independent Director	1.7yrs	US$320.06k	geen gegevens
Heidi Henson	Independent Director	1.3yrs	US$390.70k	geen gegevens
Lori Holmes-Woods	Chairperson of the Board	6.3yrs	US$671.73k	0.24% $ 2.1m

1.7yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CATX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.7 jaar), wat duidt op een nieuw bestuur.

Perspective Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

CFO & Co-Principal Financial Officer recently bought US$177k worth of stock

CEO & Director recently bought US$117k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Chief Medical Officer recently bought US$140k worth of stock

Chief Medical Officer recently bought US$189k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

Recent updates

Perspective Therapeutics Grants Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Consensus revenue estimates increase by 51%, EPS downgraded

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $49.868808 million.

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Perspective Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

CFO & Co-Principal Financial Officer recently bought US$177k worth of stock

CEO & Director recently bought US$117k worth of stock

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.998535 million.

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Perspective Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.10 loss in FY 2022)

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc.

Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors

Perspective Therapeutics, Inc. (NYSEAM:CATX) completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.

Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform

Chief Medical Officer recently bought US$140k worth of stock

Forecast to breakeven in 2026

Perspective Therapeutics, Inc. announced that it has received $20.846671 million in funding from Lantheus Alpha Therapy, LLC

Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in funding

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering.

Chief Medical Officer recently bought US$189k worth of stock

Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in Germany

Perspective Therapeutics, Inc. Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

New major risk - Financial position

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces Two Upcoming Investigator-Initiated Trials

Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear Medicine

Perspective Therapeutics, Inc. Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

New major risk - Financial position

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Second quarter 2023 earnings released

Perspective Therapeutics, Inc. Announces Termination of Jennifer Streeter as Chief Operating Officer

Less than half of directors are independent

Perspective Therapeutics, Inc.'s Cesium-131 Features at the American Brachytherapy Society's Annual Conference

Perspective Therapeutics, Inc. Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Less than half of directors are independent

Perspective Therapeutics, Inc. Announces Changes to the Board of Directors

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.009 loss in 1Q 2022)

Chairperson of the Board exercised options to buy US$129k worth of stock.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer

Isoray, Inc. Announces Executive Changes

Isoray, Inc., Annual General Meeting, Jan 12, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Isoray, Inc. to Report Q1, 2023 Results on Nov 10, 2022

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Isoray, Inc. (NYSEAM:ISR) entered into an Agreement and Plan of Merger to acquire Viewpoint Molecular Targeting, Inc.

Isoray, Inc. to Report Q4, 2022 Results on Sep 28, 2022

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd